These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 2691161)

  • 1. Autoantibodies in scleroderma.
    Pollard KM; Reimer G; Tan EM
    Clin Exp Rheumatol; 1989; 7 Suppl 3():S57-62. PubMed ID: 2691161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma).
    Reimer G
    Rheum Dis Clin North Am; 1990 Feb; 16(1):169-83. PubMed ID: 2406806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].
    Johanet C; Agostini MM; Vayssairat M; Abuaf N
    Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
    Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
    Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibody to centromere (kinetochore) in scleroderma sera.
    Moroi Y; Peebles C; Fritzler MJ; Steigerwald J; Tan EM
    Proc Natl Acad Sci U S A; 1980 Mar; 77(3):1627-31. PubMed ID: 6966403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.
    Reimer G; Scheer U; Peters JM; Tan EM
    J Immunol; 1986 Dec; 137(12):3802-8. PubMed ID: 3537125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays.
    Kipnis RJ; Craft J; Hardin JA
    Arthritis Rheum; 1990 Sep; 33(9):1431-7. PubMed ID: 2403405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The fibrillarin (Scl-34) autoantibody in systemic scleroderma].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1990; 176(1):19-26. PubMed ID: 2178987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antinucleolar antibodies in diagnostics of antiphospholipid syndrome].
    Zabek J; Palacz A; Pyka J; Krzewska I
    Pol Arch Med Wewn; 2008; 118 Suppl():25-30. PubMed ID: 19562966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scl-86, a marker antigen for diffuse scleroderma.
    van Venrooij WJ; Stapel SO; Houben H; Habets WJ; Kallenberg CG; Penner E; van de Putte LB
    J Clin Invest; 1985 Mar; 75(3):1053-60. PubMed ID: 3980727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations.
    Błaszczyk M; Jarzabek-Chorzelska M; Jabłońska S; Chorzelski T; Kołacińska-Strasz Z; Beutner EH; Kumar V
    Br J Dermatol; 1990 Oct; 123(4):421-30. PubMed ID: 2128868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies in scleroderma.
    Rothfield NF
    Rheum Dis Clin North Am; 1992 May; 18(2):483-98. PubMed ID: 1626078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
    Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
    Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serology in patients with scleroderma].
    Ullman S; Halberg P; Høier-Madsen M; Kang L; Konstantinov K; Pedersen K; Rasmussen E; Wiik A
    Ugeskr Laeger; 1993 Feb; 155(7):472-6. PubMed ID: 8465453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
    Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
    Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives.
    Harvey G; Black C; Maddison P; McHugh N
    J Rheumatol; 1997 Mar; 24(3):477-84. PubMed ID: 9058652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical relevance of autoantibodies in scleroderma.
    Ho KT; Reveille JD
    Arthritis Res Ther; 2003; 5(2):80-93. PubMed ID: 12718748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
    Oddis CV; Okano Y; Rudert WA; Trucco M; Duquesnoy RJ; Medsger TA
    Arthritis Rheum; 1992 Oct; 35(10):1211-7. PubMed ID: 1418007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil.
    Skare TL; Fonseca AE; Luciano AC; Azevedo PM
    An Bras Dermatol; 2011; 86(6):1075-81. PubMed ID: 22281893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies in systemic sclerosis.
    Vázquez-Abad D; Rothfield NF
    Int Rev Immunol; 1995; 12(2-4):145-57. PubMed ID: 7650418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.